<SEC-DOCUMENT>0001601830-24-000129.txt : 20240822
<SEC-HEADER>0001601830-24-000129.hdr.sgml : 20240822
<ACCEPTANCE-DATETIME>20240822184822
ACCESSION NUMBER:		0001601830-24-000129
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240820
FILED AS OF DATE:		20240822
DATE AS OF CHANGE:		20240822

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Borgeson Blake
		CENTRAL INDEX KEY:			0001856094
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40323
		FILM NUMBER:		241233130

	MAIL ADDRESS:	
		STREET 1:		C/O RECURSION PHARMACEUTICALS
		STREET 2:		41 S. RIO GRANDE STREET
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84101

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RECURSION PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001601830
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				464099738
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		41S RIO GRANDE STREET
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84101
		BUSINESS PHONE:		(385) 269-0203

	MAIL ADDRESS:	
		STREET 1:		41S RIO GRANDE STREET
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84101

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Recursion Pharmaceuticals, LLC
		DATE OF NAME CHANGE:	20140305
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>wk-form4_1724366895.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-08-20</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001601830</issuerCik>
        <issuerName>RECURSION PHARMACEUTICALS, INC.</issuerName>
        <issuerTradingSymbol>RXRX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001856094</rptOwnerCik>
            <rptOwnerName>Borgeson Blake</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O RECURSION PHARMACEUTICALS</rptOwnerStreet1>
            <rptOwnerStreet2>41 S. RIO GRANDE STREET</rptOwnerStreet2>
            <rptOwnerCity>SALT LAKE CITY</rptOwnerCity>
            <rptOwnerState>UT</rptOwnerState>
            <rptOwnerZipCode>84101</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>1</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Class A Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2024-08-20</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>11447</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>7.1226</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>7132769</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023.</footnote>
        <footnote id="F2">This transaction was executed in multiple trades at prices ranging from $6.99 to $7.31. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/Jonathan Golightly, attorney-in-fact</signatureName>
        <signatureDate>2024-08-22</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
